Galectin Therapeutics Inc
GALT
Company Profile
Business description
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Contact
4960 Peachtree Industrial Boulevard
Suite 240
NorcrossGA30071
USAT: +1 678 620-3186
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
15
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,006.80 | 116.00 | 1.30% |
| CAC 40 | 7,822.67 | 0.67 | 0.01% |
| DAX 40 | 24,289.51 | 81.42 | -0.33% |
| Dow JONES (US) | 44,342.19 | 142.30 | -0.32% |
| FTSE 100 | 8,992.12 | 19.48 | 0.22% |
| HKSE | 24,825.66 | 326.71 | 1.33% |
| NASDAQ | 20,895.65 | 10.01 | 0.05% |
| Nikkei 225 | 39,819.11 | 82.08 | -0.21% |
| NZX 50 Index | 12,880.40 | 25.01 | -0.19% |
| S&P 500 | 6,296.79 | 0.57 | -0.01% |
| S&P/ASX 200 | 8,757.20 | 118.20 | 1.37% |
| SSE Composite Index | 3,534.48 | 17.66 | 0.50% |